Retrouvez Macopharma au prochain congrès de la SFVTT à Marseille du 19 au 21 Novembre 2014, et venez assister à son symposium sur la technologie
THERAFLEX MB-Plasma.

Pour plus de détails, cliquez sur l’image

Tourcoing — October 29, 2014 - Macopharma is pleased to inform you that a current article from the Blood Centre of Galicia, Santiago de Compostela, Spain, entitledIn Vitro evaluation of platelet concentrates suspended in additive solution, and treated for pathogen REDUCTION: Effects of clumping formation. has been recently published in the journal “Blood Transfusion”.

The aim of this study was to analyse the relationship between the occurrence of clumping and their effect on in vitro quality of platelet concentrates suspended in additive solution.

No significant difference was found throughout storage between the groups. The LDH levels increased in both groups, but this increase was higher in the test group at the last day of testing, without significant difference on day 2. In contrast, pH values on day 2 were significantly different between test and control group. Platelet derived cytokines increased comparably during storage.

The authors conclude that:

In summary, with the PAS-E containing potassium and magnesium, glycolysis activity decreases, glucose is maintained within appropriate levels until the end of extended storage and there is a platelet activation decrease.

 The presence of « non-compacted » clumps in PCs did not appear to significantly affect the in-vitro quality of platelets suspended in plasma and PAS-E and treated with PRT.”

 

About Macopharma

Macopharma SA (“Macopharma”) is an innovator in global healthcare with expertise in the fields of transfusion and infusion. The company has become the largest supplier of in-line leucodepletion filtration sets in Europe, It is expanding its efforts in the fields of respiratory masks and cellular therapy by developing products for cell expansion, in addition to cell/organ processing and freezing. Headquartered in the Lille metropolitan area (France), Macopharma has four manufacturing facilities in Europe and their products are sold into more than 70 countries worldwide. One of Macopharma’s aims is to provide a comprehensive range for the pathogen reduction of infectious agents in plasma, platelets and red cells. This is aligned with Macopharma’s product development strategy of the continuous quest, through partnerships, for improved safety, efficacy, and quality of transfusion, infusion, masks and cellular therapy.

www.macopharma.com

About Platelet Additive Solution SSP+

Platelet concentrates (PCs) are notably used for the prevention and treatment of bleeding complications in thrombocytopenic patients. Therefore platelet quality, function, storage stability, morphology and cell integrity needs to be well maintained during processing and storage. Platelet additive solution SSP+ (PAS III-E generation) is recognised as the most suitable additive solution on the market that helps standardise platelet concentrates and improves storage conditions for up to 7 days. SSP+ is compatible with manual methods and Backlab technologies for the preparation of PCs from buffy-coat and has been validated to be used with all Pathogen Reduction technologies.

www.bloodsafety.macopharma.com

Tourcoing — October 8, 2014 - Macopharma is pleased to inform you that a current article from the Coordinating Haemovigilance Centre, Athens, Greece, entitled “Haemovigilance data on the use of methylene blue virally inactivated fresh frozen plasma with the Theraflex MB-Plasma System in comparison to quarantine plasma: 11years’ experience.” has been recently published in the journal “Transfusion Medicine”1.

The aim of this study was to analyse cumulative haemovigilance data in order to compare the two secured therapeutic plasmas that have been in use for more than 11 years in Greece – methylene blue-treated fresh frozen plasma (MB-FFP) and quarantine fresh frozen plasma (Q-FFP) – regarding safety and adverse events.

The incidence of adverse events was higher with Q-FFP (1:3 620) than MB-FFP (1: 24 593) by a factor of 6.79. Allergic adverse events were also commoner with Q-FFP (1: 7 489) than with MB-FFP (1:24 593), by a factor of 3.28. All adverse reactions experienced by the MB plasma recipients were considered to be mild.

The authors conclude that “haemovigilance over 11years has demonstrated the long-term safety of MB-FFP in comparison to untreated quarantine FFP. In addition to lowering the adverse event rate, implementing the system on a national scale in at-risk countries would presumably reduce the transmission of severe viral infections including emerging infectious diseases by transfusion.”

About Macopharma

Macopharma SA (“Macopharma”) is an innovator in global healthcare with expertise in the fields of transfusion and infusion. The company has become the largest supplier of in-line leucodepletion filtration sets in Europe, It is expanding its efforts in the fields of respiratory masks and cellular therapy by developing products for cell expansion, in addition to cell/organ processing and freezing. Headquartered in the Lille metropolitan area (France), Macopharma has four manufacturing facilities in Europe and their products are sold into more than 70 countries worldwide. One of Macopharma’s aims is to provide a comprehensive range for the pathogen reduction of infectious agents in plasma, platelets and red cells. This is aligned with Macopharma’s product development strategy of the continuous quest, through partnerships, for improved safety, efficacy, and quality of transfusion, infusion, masks and cellular therapy.

www.macopharma.com

About THERAFLEX MB-Plasma 

The THERAFLEX MB-Plasma System has a Class III CE Mark (available for sale in countries where the CE mark is accepted) and is not currently available for sale in the United States. It is a user-friendly in-house treatment for single units of plasma. The GMP-conforming procedure is adapted for the inactivation of FFP from aphaeresis or whole blood plasma. The MB plasma system uses a combination of a membrane filter Plasmaflex PLAS4, (which removes residual leucocytes, red cells, platelets and aggregates, intra-cellular viruses and minimises the amount of microvesicles and microparticles), a dry Methylene Blue pill, visible light and a Blueflex Methylene Blue removal filter.

www.bloodsafety.macopharma.com

1.   Politis C, Kavallierou L, Hantziara S, Parara M, Zervou E, Katsarou O, Hatzitaki M, Fountouli P, Gioka A, Tzioura K, Koumarianos S, Asariotou M, Richardson C. Haemovigilance data on the use of methylene blue virally inactivated fresh frozen plasma with the Theraflex MB-Plasma System in comparison to quarantine plasma: 11 years’ experience. Transfus Med 2014.

From 14th to 16th October 2014 , Macopharma will participate in the 24th Medical Devices National Days organised by Euro-Pharmat. Come and meet us at booth 77C to discover our new products for the safety and control of hospital preparations.

We look forward to representing to the Americas and many visitors from multiple international countries the many automation options Macopharma has to offer, in addition to the cord blood and whole blood collection and processing solutions we provide to over 70 countries worldwide.

Please come visit us on our booth number 803. Share with us your needs and let us know what solutions we can provide to you today, and tomorrow.